Related Experiment Video
Updated: May 16, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
Perinatal Antibiotic Exposure and Respiratory Outcomes in Children Born Preterm
Ingmar Fortmann1,2, Amrei Welp3, Nele Hoffmann1
1Department of Pediatrics, University Hospital of Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Insights
Repeated antibiotic exposure in preterm infants is linked to poorer lung function and increased asthma risk by early school age. This highlights the need for targeted respiratory support in high-risk neonates.
Area of Science:
- Neonatal Medicine
- Pediatric Pulmonology
- Epidemiology
Background:
- Animal studies suggest a link between early antibiotic exposure and obstructive airway disease.
- Data on this association in premature infants are limited, necessitating further investigation.
Purpose of the Study:
- To determine if repeated perinatal antibiotic exposure in very low birth weight (VLBW) preterm neonates is associated with obstructive airway disease at early school age.
Main Methods:
- A population-based, multicenter cohort study involving VLBW preterm neonates (22-36 weeks gestation) from 58 German Neonatal Network centers.
- Antibiotic exposure was quantified using an antibiotic risk score (ARS), with post hoc analysis restricted to cesarean-born participants.
- Lung function (FEV1, FVC z scores) and childhood asthma episodes were assessed at 5-7 years of age.
Main Results:
- Higher antibiotic risk scores were associated with significantly lower forced expiratory volume in 1 second (FEV1) z scores at early school age.
- Increased exposure levels correlated with impaired forced vital capacity (FVC) z scores.
- Higher antibiotic exposure was also linked to a significantly increased risk of early childhood asthma episodes.
Conclusions:
- Multiple episodes of perinatal antibiotic exposure are associated with impaired lung function in preterm-born children.
- Early identification of high-risk neonates is crucial for implementing targeted strategies to support respiratory health and optimize long-term outcomes.
Importance:
Animal models suggest a link between early antibiotic exposure and obstructive airway disease, but corresponding data for premature infants are lacking.
Objective:
To investigate whether repeated perinatal antibiotic exposure in preterm neonates with very low birth weight (VLBW) is associated with obstructive airway disease at early school age.
Design, Setting, And Participants:
In this population-based, multicenter cohort study, VLBW preterm neonates (22 weeks 0 days' to 36 weeks 6 days' gestation with birth weight <1500 g) were enrolled in 58 German Neonatal Network (GNN) centers from January 2009 to March 2017 and received a standardized follow-up at 5 to 7 years of age. To assess the sequential outcomes of antibiotic exposures, the post hoc analysis was restricted to participants born by cesarean delivery. Data were analyzed from May 2024 to February 2025.
Exposure:
Perinatal antibiotic exposure, defined by an antibiotic risk score (ARS).
Main Outcome And Measures:
The primary end point was the forced expiratory volume in 1 second (FEV1) z score at 5 to 7 years of age. The low-risk (ARS I) group was exclusively exposed to surgical antimicrobial prophylaxis (SAP) given to the mother before cesarean delivery. The intermediate-risk (ARS II) group was exposed to maternal SAP and postnatal antibiotic treatment of the neonate, while the high-risk (ARS III) group was additionally exposed to antenatal maternal treatment. Secondary outcomes included forced vital capacity (FVC) z score and childhood asthma episodes. Univariate and linear regression models were used to analyze outcome measures.
Results:
Of 3820 VLBW preterm-born children with follow-up at age 5 to 7 years (median gestational age, 28.4 weeks [IQR, 26.6-30.3 weeks]; 1948 [51.0%] male; 1382 [36.2%] from a multiple birth), 3109 (81.4%) were born by cesarean delivery. Of these children, 292 (9.4%) were classified into ARS I, 1329 (42.7%) into ARS II, and 1488 (47.9%) into ARS III. Higher ARS levels were associated with lower FEV1 z scores at early school age (ARS II vs I: β, -0.31 [95% CI, -0.59 to -0.02]; P = .03; ARS III vs II: β, -0.27 [95% CI, -0.46 to -0.08]; P = .006). In the secondary analysis, a higher exposure level (ARS III vs II) was associated with impaired FVC z scores (β, -0.23; 95% CI, -0.43 to -0.03; P = .02) and an increased risk of early childhood asthma episodes (odds ratio, 1.91; 95% CI, 1.32-2.76; P = .001).
Conclusions And Relevance:
In this GNN cohort study, multiple episodes of perinatal antibiotic exposure were associated with impaired lung function in preterm-born children at early school age. Early identification of high-risk neonates may enable targeted strategies to support respiratory health and optimize long-term outcomes.
Related Concept Videos
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Breathing
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment

